Related Experiment Video

Updated: Apr 11, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K

Activating MET kinase rearrangements in melanoma and Spitz tumours

Iwei Yeh1, Thomas Botton1, Eric Talevich1

  • 11] Departments of Dermatology and Pathology, and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA [2] Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA.

Nature Communications
|May 28, 2015
PubMed

Insights

Researchers discovered novel MET gene fusions in melanocytic tumors, activating key cancer pathways. These fusions represent a potential therapeutic target for a subset of melanoma patients lacking other treatment options.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Oncogenic gene fusions are crucial in cancer development, serving as biomarkers and therapeutic targets.
  • Melanoma treatment options are limited for certain patient subsets, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To identify and characterize novel oncogenic gene fusions involving the MET gene in melanocytic tumors.
  • To investigate the functional consequences of these MET fusions on cellular signaling pathways.
  • To assess the efficacy of MET inhibitors against tumors harboring these fusions.

Main Methods:

  • Genomic rearrangement analysis to identify MET fusions in melanocytic tumors.
  • Functional characterization of fusion proteins using cell-based assays.
  • Assessment of pathway activation (MAPK, PI3K, PLCγ1) by fusion proteins.
  • In vitro testing of MET inhibitors (cabozantinib, PF-04217903) against MET fusion kinases.

Main Results:

  • Six distinct melanocytic tumors with genomic rearrangements of MET were identified, fusing its kinase domain to various N-terminal partners.
  • These tumors lacked activating mutations in known melanoma oncogenes.
  • Functional analysis of TRIM4-MET and ZKSCAN1-MET fusions demonstrated constitutive activation of MAPK, PI3K, and PLCγ1 pathways.
  • MET inhibitors cabozantinib and PF-04217903 effectively blocked the activity of these fusion kinases at nanomolar concentrations.

Conclusions:

  • MET fusion kinases represent a novel oncogenic driver in a rare subset of melanocytic tumors.
  • These findings identify MET fusion kinases as a potential therapeutic target for melanoma patients.
  • Targeted therapy with MET inhibitors offers a promising avenue for treating these specific melanoma cases.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K